🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9 results for “Otsuka Novel Products GmbH” Clear

  1. AVP-786 matching Placebo, AVP-786, AVP-786

    Otsuka Novel Products GmbH

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  2. AVP-786 matching placebo, AVP-786

    Otsuka Novel Products GmbH

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  3. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Novel Products GmbH

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  4. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Novel Products GmbH

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  5. Tolvaptan

    Otsuka Novel Products GmbH

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  6. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Novel Products GmbH

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  7. A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

    Otsuka Novel Products GmbH

    Tuberculosis

    phase 1 other active

    1 trial

  8. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Novel Products GmbH

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  9. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Novel Products GmbH

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources